131513-64-9

Usage

Uses

Used in Pharmaceutical Synthesis:
1-(2-FLUORO-PHENYL)-BUTANE-1,3-DIONE is used as an intermediate in the synthesis of various organic compounds and pharmaceuticals, contributing to the development of new drugs and therapies.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 1-(2-FLUORO-PHENYL)-BUTANE-1,3-DIONE is utilized as a key component in the design and synthesis of novel drug candidates, potentially leading to advancements in treatment options for various diseases and conditions.
Used in Drug Development:
The presence of the fluorine atom in the phenyl ring of 1-(2-FLUORO-PHENYL)-BUTANE-1,3-DIONE makes it a valuable compound in drug development processes, where it can be used to enhance the properties of pharmaceuticals, such as their efficacy, selectivity, and bioavailability.

InChI:InChI=1/C10H9FO2/c1-7(12)6-10(13)8-4-2-3-5-9(8)11/h2-5H,6H2,1H3

Upstream product

• 445-27-2 2'-Fluoroacetophenone 
• 141-78-6 ethyl acetate 
• 446-52-6 2-Fluorobenzaldehyde 
• 67-64-1 acetone 
• 80277-41-4 2-fluorobenzoyl cyanide 

Downstream Products

• 131513-25-2 3-(4-Morpholinylmethyl)-5-methyl-6-(2-fluorobenzoyl)-2,3-dihydropyrrolo[1,2,3-de]-1,4-benzoxazine 
• 131513-26-3 3-(4-morpholinylmethyl)-5-methyl-6-(2-fluorobenzoyl)-2,3-dihydropyrrolo[1,2,3-de]-1,4-benzoxazine methanesulfonate 
• 107504-98-3 2-(5,6-Dihydro-imidazo[2,1-b]thiazol-3-yl)-1-(2-fluoro-phenyl)-ethanone; hydrobromide 
• 107505-05-5 2-[5,6-Dihydro-imidazo[2,1-b]thiazol-(3E)-ylidene]-1-(2-fluoro-phenyl)-ethanone 

Relevant academic research and scientific papers

Proline-catalyzed aldol reactions of acyl cyanides with acetone: An efficient and convenient synthesis of 1,3-diketones

The aldol-type addition of acetone towards (un)substituted benzoyl, heteroarylcarbonyl or α,β-unsaturated acyl cyanides was efficiently catalyzed by l-proline (30 mol %) to give 2-hydroxy-4-oxo-2-substituted pentanenitriles. Upon the treatment with sodium hydroxide, the adducts transformed to 1,3-diketones in good-to-excellent yield, furnishing an efficient and convenient method for the regioselective synthesis of 1,3-diketones.

I2-Promoted [3+2] Cyclization of 1,3-Diketones with Potassium Thiocyanate: a Route to Thiazol-2(3H)-One Derivatives

An I2-promoted strategy has been developed for the synthesis of thiazol-2(3H)-one derivatives from 1,3-diketones with potassium thiocyanate. This [3+2] cyclization reaction involves C?S and C?N bond formation and exhibits good functional group tolerance. A series of thiazol-2(3H)-one derivatives are obtained in moderate to good yields. (Figure presented.).

Rhodium(ii)-catalysed generation of cycloprop-1-en-1-yl ketones and their rearrangement to 5-aryl-2-siloxyfurans

Donor-acceptor cyclopropenes formed from enoldiazoketones undergo catalytic rearrangement to 5-aryl-2-siloxyfurans via a novel mechanism that involves a nucleophilic addition of the carbonyl oxygen to the rhodium-activated cyclopropene.

Direct synthesis of 1,3-dicarbonyl compounds via radical coupling of aldehydes with ketones under metal-free conditions

An efficient approach for the synthesis of 1,3-diketones from aldehydes and ketones has been developed using Bu4NI (TBAI) as the catalyst. In the presence of DTBP-TBHP/p-TsOH, aldehydes undergo radical coupling with ketones to provide the desired products in moderate to high yields at 120 °C. Although various substituents on the aromatic ring of aldehydes are well tolerable under the standard reaction conditions, the protocol is limited by the scope of ketones. The method exhibits advantages in terms of the easy access of the starting materials, operational simplicity, functional group tolerance, and the absence of metal catalyst.

Discovery and structure-activity relationships study of novel thieno[2,3-b]pyridine analogues as hepatitis C virus inhibitors

Current treatment for hepatitis C is barely satisfactory, there is an urgent need to develop novel agents for combating hepatitis C virus infection. This study discovered a new class of thieno[2,3-b]pyridine derivatives as HCV inhibitors. First, a hit compound characterized by a thienopyridine core was identified in a cell-based screening of our privileged small molecule library. And then, structure activity relationship study of the hit compound led to the discovery of several potent compounds without obvious cytotoxicity in vitro (12c, EC50 = 3.3 μM, SI >30.3, 12b, EC50 = 3.5 μM, SI >28.6, 10l, EC50 = 3.9 μM, SI >25.6, 12o, EC 50 = 4.5 μM, SI >22.2, respectively). Although the mechanism of them had not been clearly elucidated, our preliminary optimization of this class of compounds had provided us a start point to develop new anti-HCV agents.

Triketoacid inhibitors of HIV-integrase: A new chemotype useful for probing the integrase pharmacophore

Integrase is one of three enzymes expressed by HIV and represents a validated target for therapy. This study reports on the discovery of a new triketoacid-based chemotype that selectively inhibits the strand transfer reaction of HIV-integrase. SAR studies showed that the template binds to integrase in a manner similar to the diketoacid-based inhibitors. Moreover, comparison of the new chemotype to two different diketoacid templates led us to propose two aryl-binding domains in the inhibitor binding site. This information was used to design a new diketoacid template with improved activity against the enzyme.

Substituted oxazoles and thiazoles derivatives as hPPARγ and hPPARα activators

The present invention discloses compounds of formula (I), and tautomeric forms, pharmaceutically acceptable salts, or solvates thereof. Preferably, the compounds of the invention are dual activators of hPPARγ and hPPAR{acute over (α)}.